BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27569947)

  • 21. A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.
    Winquist E; Wilson JJ; Dorreen M; Wong R; Jonker D; Iscoe N
    Can J Urol; 2004 Dec; 11(6):2445-9. PubMed ID: 15636670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
    J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
    Tinker A; Winquist E; Canil C; Moore M; Murray RN; Chi KN
    Am J Clin Oncol; 2006 Feb; 29(1):3-7. PubMed ID: 16462494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
    Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
    JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
    Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.
    Türkölmez K; Bedük Y; Baltaci S; Göğüş C; Göğüş O
    Eur Urol; 2003 Dec; 44(6):682-6. PubMed ID: 14644120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
    Mallick JA; Ali SA; Siddiqui N; Fareed A
    J Pak Med Assoc; 2003 Nov; 53(11):547-52. PubMed ID: 14738263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
    Jan AS; Dolan DE; Lombardi K; Gupta S
    Clin Genitourin Cancer; 2016 Jun; 14(3):e257-63. PubMed ID: 26462439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation.
    Meliani E; Lapini A; Serni S; Corvino C; Carini M
    Urol Int; 2003; 71(1):37-40. PubMed ID: 12845258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.
    Lorusso V; Pollera CF; Antimi M; Luporini G; Gridelli C; Frassineti GL; Oliva C; Pacini M; De Lena M
    Eur J Cancer; 1998 Jul; 34(8):1208-12. PubMed ID: 9849481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.